Background: Biomarkers promise to significantly improve the differential diagnosis of Alzheimer's disease (AD). Plasma biomarkers, such as phosphorylated tau (p-tau), have shown potential in diagnosing AD with high accuracy. Unlike the widely-used [18 F]FDG-PET diagnostic biomarker in clinical practice, plasma p-tau is specific to AD and can provide an affordable and scalable diagnostic tool.
Method: We conducted a retrospective analysis of individuals with atypical dementia, and/or early-onset dementia cases, who were assessed at a specialized memory clinic. All participants underwent measurements of CSF Aβ42, p-tau181, and total tau levels, as well as brain [F]FDG-PET scans and plasma p-tau217 measurement. The [F]FDG-PET data was visually examined by two nuclear medicine experts to determine whether they were compatible with AD. CSF biomarker results were categorized as either AD biomarker positive or negative. Contingency analysis was performed to assess the relationships between PET scan interpretation and fluid biomarkers (plasma p-tau217 and CSF p-tau181 and Aβ42). CSF biomarker and amyloid-PET were treated as the reference standard.
Result: 81 subjects with atypical dementia had CSF AD biomarker evaluation, [F]FDG-PET rating, and plasma p-tau217 assessment. Both [F]FDG-PET and plasma p-tau217 had high levels of agreement with reference standard AD biomarkers ([F]FDG-PET: 71%; plasma p-tau217: 81%). Although both biomarkers had similar specificity for AD ([F]FDG-PET:70%, plasma p-tau217:70%), plasma p-tau217 had higher sensitivity for abnormal AD (97%). Overall accuracy was also higher for plasma p-tau217 (AUC=84%, 95%CI = 0.75- 0.93). The same pattern of results was observed when using amyloid-PET as the reference standard.
Conclusion: Our study provides evidence that plasma p-tau217 has excellent diagnostic performance for AD in individuals with early-onset or atypical dementia evaluated in specialized settings. Nevertheless, the topographical information from [F]FDG-PET may give complementary information.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/alz.093116 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Alzheimer's disease (AD) impacts over 50 million individuals and imposes a substantial burden on patients, caregivers, and society at large. Recent research suggests that AD is a continuum comprising preclinical, prodromal, and dementia stages, with underlying pathology manifesting well before symptoms appear. Early and accurate diagnosis is therefore crucial for optimal clinical outcomes; yet current diagnostic methods, such as neuroimaging and cerebrospinal fluid lumbar puncture, are expensive and invasive.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Clinical Memory Research Unit, Lund University, Lund, Sweden.
Background: Fluid biomarkers represent an informative and cost-effective way to detect and monitor Alzheimer's disease (AD). However, as we recently showed, the overall proteome average in CSF exhibits a non-disease related average signal (inter-individual variability), which can reduce the precision of concentration based CSF AD biomarkers. Now, we therefore investigate if several already high performing CSF and plasma AD biomarkers can be improved by normalizing their concentration to a reference protein (e.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Department of Psychiatry and Psychotherapy, Universitätsklinikum Erlangen and Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany.
Background: In the context of Alzheimer's disease (AD), blood-based biomarkers have become increasingly important for various clinical purposes, such as screening patients and tracking the progression of the disease. Tau is a protein that stabilizes microtubules in nerve cells. In AD, different isoforms of tau become hyperphosphorylated, leading to the formation of neurofibrillary tangles, which are a key pathological feature of the AD.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden.
Background: We assessed the efficacy of four plasma phospho-tau217 (p-tau217) biomarkers in a head-to-head comparison, and against two clinically available CSF biomarkers for Alzheimer's disease (AD).
Method: Samples were analyzed from 1009 individuals from the Swedish BioFINDER-2 cohort (Table 1). We included the following biomarkers: %p-tau217, p-tau217 (both mass-spectrometry), p-tau217, p-tau217 (both immunoassays), CSF p-tau181 and p-tau181/Aβ42 (Elecsys).
Background: Biomarkers, such as blood p-tau181, p-tau217, and p-tau231, have been created and verified to mirror the pathophysiology of tau and amyloid-β (Aβ) in the brain . Sleep spindles are known to contribute to memory consolidation and generalization and may therefore be a promising biomarker in preclinical Alzheimer's Disease (AD) . The present study investigated the relationship between sleep spindles and p-tau levels in cognitively healthy older African Americans.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!